All holdings
Organon & Co OGN
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Share price change by quarter -7.6% Q3 ’24
-22.0% Q4 ’24
-0.2% Q1 ’25
-35.0% Q2 ’25
+10.3% Q3 ’25
-32.9% Q4 ’25
-16.5% Q1 ’26
+126.0% Q2 ’26
Q3 ’24: -7.6%; Q4 ’24: -22.0%; Q1 ’25: -0.2%; Q2 ’25: -35.0%; Q3 ’25: +10.3%; Q4 ’25: -32.9%; Q1 ’26: -16.5%; Q2 ’26: +126.0% Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.
Managers holding it, by quarter 1 Q4 ’23
1 Q1 ’24
1 Q2 ’24
1 Q3 ’24
1 Q4 ’24
1 Q1 ’25
1 Q2 ’25
1 Q3 ’25
1 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes Organon & Co.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding Organon & Co Manager Portfolio▼ Value Change Held for Kahn Brothers 5.7%$36.2m $36.2m ▼ Trimmed -52%21 qtrs
Download the holders: CSV · JSON · Markdown
Directors buying and selling Open-market trades by directors, officers and 10% holders over the last 12 months. How this works From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Sort by Date (high to low) Date (low to high) Who (Z–A) Who (A–Z) Shares (high to low) Shares (low to high) Value (high to low) Value (low to high) Insider purchases and sales of Organon & Co Date▼ Who Bought or sold Shares Price Value Filing 5 Aug 2026 Drinane Juliana PapaHead of Mfg & Supply ▼ Sold 14,761 $13.57 $200k Form 4
About the company Sector Health care · Pharmaceutical Preparations Financial year ends 31 December Shares outstanding 263m at 24 Jul 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit $7.8bn 2019
$6.5bn 2020
$6.3bn 2021
$6.2bn 2022
$6.3bn 2023
$6.4bn 2024
$6.2bn 2025
2019: $7.8bn; 2020: $6.5bn; 2021: $6.3bn; 2022: $6.2bn; 2023: $6.3bn; 2024: $6.4bn; 2025: $6.2bn Organon & Co revenue and net income by year Year Revenue Net income 2025 $6.2bn $187m 2024 $6.4bn $864m 2023 $6.3bn $1.0bn 2022 $6.2bn $917m 2021 $6.3bn $1.4bn 2020 $6.5bn $2.2bn 2019 $7.8bn $3.2bn
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.